Wall Street brokerages predict that Sonendo, Inc. (NYSE:SONX – Get Rating) will post ($0.57) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Sonendo’s earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.53). The company is expected to announce its next earnings results after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Sonendo will report full year earnings of ($2.20) per share for the current financial year, with EPS estimates ranging from ($2.30) to ($2.06). For the next year, analysts expect that the company will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.63) to ($1.47). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Sonendo.
Sonendo (NYSE:SONX – Get Rating) last posted its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.21). The firm had revenue of $9.89 million for the quarter, compared to analyst estimates of $9.80 million.
NYSE SONX opened at $2.80 on Thursday. Sonendo has a one year low of $2.60 and a one year high of $12.24. The company has a 50 day simple moving average of $3.78. The company has a quick ratio of 6.19, a current ratio of 6.75 and a debt-to-equity ratio of 0.37.
Several large investors have recently modified their holdings of SONX. Northern Trust Corp purchased a new stake in shares of Sonendo during the 4th quarter worth approximately $76,000. Bank of America Corp DE acquired a new position in shares of Sonendo in the 4th quarter valued at $31,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Sonendo in the 4th quarter valued at $4,796,000. Ensign Peak Advisors Inc acquired a new position in shares of Sonendo in the 4th quarter valued at $958,000. Finally, General Atlantic L.P. acquired a new position in shares of Sonendo in the 4th quarter valued at $18,822,000. Institutional investors and hedge funds own 80.42% of the company’s stock.
About Sonendo (Get Rating)
Sonendo, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment device for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure.
- Get a free copy of the StockNews.com research report on Sonendo (SONX)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sonendo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonendo and related companies with MarketBeat.com's FREE daily email newsletter.